Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
82.1M
-
Shares change
-
+15.3M
-
Total reported value, excl. options
-
$2.31B
-
Value change
-
+$442M
-
Put/Call ratio
-
0.33
-
Number of buys
-
93
-
Number of sells
-
-36
-
Price
-
$28.21
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q2 2023
148 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q2 2023.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.1M shares
.
Largest 10 shareholders include Matrix Capital Management Company, LP (14M shares), FMR LLC (10.6M shares), EVENTIDE ASSET MANAGEMENT, LLC (6.88M shares), VANGUARD GROUP INC (4.93M shares), BlackRock Inc. (3.95M shares), STATE STREET CORP (3.15M shares), Capital International Investors (3.13M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.68M shares), Avidity Partners Management LP (2.33M shares), and CITADEL ADVISORS LLC (2.13M shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.